Lucid Diagnostics Inc. (LUCD) · Oct 16, 2026 · Delisting
$1 bid-price deficiency — Below $1 for 30 consecutive business days; 180 days to cure
Lucid Diagnostics received a Nasdaq delisting warning after 30 days below $1, adding a compliance deadline to its reimbursement-driven growth story.
Lucid is a commercial-stage cancer-prevention diagnostics company working to scale its EsoGuard test and EsoCheck collection device; its recent disclosures also show that the business depends heavily on reimbursement expansion and additional capital.
The filing adds a real listing-compliance overhang. Nasdaq says LUCD traded below the $1 minimum bid price for 30 straight business days through October 9. Lucid now has until April 12, 2027, to maintain at least $1 for 10 consecutive business days; otherwise, it could face another review and potentially delisting.
This is a complication, not an immediate operating disruption. The shares remain listed and trading uninterrupted for now. 〔0〕 But the deadline creates pressure for actions such as a reverse split or other measures to restore compliance, potentially competing with the company’s need to fund commercialization and reach reimbursement milestones.
The immediate news is worse than the standing story, but the damage is mainly financial-market access. The notice does not change EsoGuard demand, reimbursement status, or test performance; it does add another execution problem for a company already trying to scale revenue before its cash and financing needs become more acute. Lucid says it will consider all available compliance options, but it does not specify a plan yet. 〔1〕
Bottom line: Lucid’s diagnostic rollout continues, but Nasdaq noncompliance adds a meaningful deadline and financing-pressure risk to an already capital-dependent business story. This matters because failure to restore the price could threaten the company’s access to a national exchange, even though delisting is not imminent today.
Regain $1 bid price by April 12, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!